Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €453.42 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 10:30 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008

France

Phone: 33 1 53 77 40 00

Fax: 33 1 53 77 42 96

h Dubai Investment. Globalpharma Company LLC is a company based in Dubai with activities in various countries of the region. Vaccine Products Sanofi Pasteur, the vaccines division of the company, offers a range of vaccines. In 2014, Sanofi Pasteur provided approximately 1 billion doses of vaccines. In the U.S., Sanofi Pasteur is the major producer of influenza and meningitis vaccines. In Europe, Sanofi Pasteur's vaccine products are developed and marketed by Sanofi Pasteur MSD, a joint venture that serves 19 countries. Sanofi Pasteur MSD also distributes Merck vaccines, such as Gardasil and Zostavax. Sanofi Pasteur keeps expanding in Asia, Latin America, Africa, the Middle East and Eastern Europe. In addition, Sanofi Pasteur is a key supplier to publicly funded international markets, such as United Nations Children's Fund, the Pan American Health Organization, and the Global Alliance for Vaccines and Immunization. Pediatric, Combination and Poliomyelitis (Polio) Vaccines Sanofi Pasteur offers pediatric vaccines in both mature and emerging markets with a portfolio of standalone and combination vaccines protecting against approximately six diseases in a single injection. Pentaxim is a pediatric combination vaccine protecting against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (Hib). As of December 31, 2014, approximately 200 million doses of Pentaxim had been distributed in approximately 100 countries, and the vaccine has been included in the national immunization programs of approximately 25 countries. Hexaxim is the only fully liquid, ready to use, 6-in-1 (hexavalent) pediatric vaccine that provides protection against diphtheria, tetanus, pertussis, polio, Hib and hepatitis B. In 2013, the EMA approved this hexavalent pediatric vaccine in the E.U., where it is sold under the brand name Hexyon in Western Europe by Sanofi Pasteur MSD and under the brand name Hexacima in Eastern Europe by Sanofi Pasteur. Hexaxim is the combination vaccine, including acellular pertussis and inactivated polio vaccines prequalified by the World Health Organization. Pentacel is a pediatric combination vaccine protecting against five diseases (diphtheria, tetanus, pertussis, polio and Hib). Pediacel is a fully liquid pentavalent vaccine protecting against diphtheria, tetanus, pertussis, polio and Hib. Act-HIB, for the prevention of Hib, is also an important growth driver within the pediatric product line. Quadracel is a combination vaccine against diphtheria, tetanus, pertussis and polio. It is used as a booster to be administered as the fifth dose in the primary series of vaccines, allowing children to complete the entire childhood schedule with as few injections as possible. Quadracel is already available in Canada and Australia. A marketing authorization application for Quadracel was submitted to the FDA in 2014. Shan5, developped by Shantha, is a fully-liquid 5-in-1 vaccine, protecting against five diseases (diphtheria, tetanus, pertussis, polio and Hepatitis B). Shan5 was launched on the Indian market in 2014. Sanofi Pasteur is co-developing with Merck & Co., Inc., a hexavalent combination vaccine (6-in-1 vaccine PR5i) designed to protect against diphtheria, tetanus, pertussis, polio, Hib and hepatitis B. An application for licensure was submitted to the FDA in the U.S. in August 2014 and to the EMA in Europe in January 2015. PR5i should be the first hexavalent vaccine in the U.S. market. Squarekids is developed with the company’s partner, Kitasato Daiichi Sankyo Vaccine. The commercial launch of this product is expected in 2015. Influenza Vaccines Sanofi Pasteur engages in the production and marketing of influenza vaccines with approximately 220 million doses delivered in 2014. Fluzone High-Dose vaccine is primarily designed to generate an immune response against influenza in people aged 65 and older and provide greater protection against influenza. Fluzone Quadrivalent vaccine is a quadrivalent inactivated influenza vaccine containing two type A antigens and two type B antigens. In 2013, Sanofi Pasteur obtained FDA authorization for Fluzone Quadrivalent to be

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHPP:FP €453.42 EUR 0.00

RHPP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $157.03 USD +0.77
Bayer AG €131.11 EUR +1.20
Bristol-Myers Squibb Co $66.48 USD +1.88
GlaxoSmithKline PLC 1,456 GBp +2.50
Medtronic PLC $76.70 USD +0.38
View Industry Companies
 

Industry Analysis

RHPP

Industry Average

Valuation RHPP Industry Range
Price/Earnings 28.0x
Price/Sales 3.4x
Price/Book 2.1x
Price/Cash Flow 17.7x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-TITR PART10%87, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.